Sign in

NCT06637072CompletedPhase 4

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC

Source: ClinicalTrials.gov · Last updated 6 Apr 2026

Brief summary (registry, in English)

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
23 (actual)
First submitted
7 Oct 2024
Start date
10 Dec 2024
Primary completion date
19 Feb 2026
Lead sponsor
argenx
NCT number
NCT06637072

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 23
  • From 10 Dec 2024 to the primary completion date, 19 Feb 2026
  • 13 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk

Other

  • Types of other polyneuropathy other than CIDP

Who the study is looking for

  • Is at least 18 years of age and the local legal age of consent
  • Is diagnosed with CIDP (confirmed or possible CIDP) according to the criteria of the European Academy of Neurology/Peripheral Nerve Society
  • Is being treated with IVIg every 3-6 weeks, on a stable dose and dosing interval (between 0.5-2 g/kg) for at least 3 doses
  • If receiving oral corticosteroids, this should be at a stable dose of less than 20 mg a day or less than 40 mg every other day, for at least a month.
  • If receiving nonsteroidal immunosuppressive medication, this should be at a stable dose for at least 3 months

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Neuromuscular Research Institute
Coordinator of this site? Confirm its status		AustinUnited StatesUnknown status
Erlanger Neuroscience Institute
Coordinator of this site? Confirm its status		ChattanoogaUnited StatesUnknown status
Northwestern Memorial Hospital
Coordinator of this site? Confirm its status		ChicagoUnited StatesUnknown status
Northwest Houston Neurology - Cypress
Coordinator of this site? Confirm its status		CypressUnited StatesUnknown status
Horizon Clinical Research: Gill Neuroscience
Coordinator of this site? Confirm its status		CypressUnited StatesUnknown status
Cedar Health Research - Dallas
Coordinator of this site? Confirm its status		DallasUnited StatesUnknown status
Velocity Clinical Research
Coordinator of this site? Confirm its status		LafayetteUnited StatesUnknown status
Neurology Associates PA
Coordinator of this site? Confirm its status		MaitlandUnited StatesUnknown status
Visionary Investigators Network
Coordinator of this site? Confirm its status		MiamiUnited StatesUnknown status
Vanderbilt University Medical Center
Coordinator of this site? Confirm its status		NashvilleUnited StatesUnknown status
SRI International - ClinEdge
Coordinator of this site? Confirm its status		PlymouthUnited StatesUnknown status
Velocity Clinical Research
Coordinator of this site? Confirm its status		RaleighUnited StatesUnknown status
MedStar Washington Hospital Center
Coordinator of this site? Confirm its status		Washington D.C.United StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.